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Background: The purpose of this study was to develop a sustained drug-release model for 
water-soluble drugs using silica nanoparticles.
Methods: Hollow-type mesoporous silica nanoparticles (HMSNs) were prepared using Na2CO3 
solution as the dissolution medium for the first time. The water-soluble compound, silybin 
meglumine, was used as the model drug. The Wagner–Nelson method was used to calculate 
the in vivo absorption fraction.
Results: The results of transmission electron microscopy and nitrogen adsorption revealed 
that the empty HMSNs had uniformly distributed particles of size 50–100 nm, a spherical 
appearance, a large specific surface area (385.89 ± 1.12 m2/g), and ultralow mean pore size 
(2.74 nm). The highly porous structure allowed a large drug-loading rate (58.91% ± 0.39%). In 
0.08 M Na2CO3 solution, silybin meglumine-loaded HMSNs could achieve highly efficacious 
and long-term sustained release for 72 hours in vitro. The results of in vitro–in vivo correla-
tion revealed that HMSNs in 0.08 M Na2CO3 solution had a correlation coefficient R2 value 
of 0.9931, while those of artificial gastric juice and artificial intestinal juice were only 0.9287 
and 0.7689, respectively.
Conclusion: The findings of in vitro–in vivo correlation indicate that HMSNs together with 
Na2CO3 solution could achieve an excellent linear relationship between in vitro dissolution and 
in vivo absorption for 72 hours, leading to a promising model for sustained release of water-
soluble drugs.
Keywords: hollow-type mesoporous silica nanoparticle, silybin meglumine, in vitro dissolution, 
in vivo absorption, in vitro–in vivo correlation
Introduction
Over the past few decades, mesoporous silica nanoparticles have played an   important 
role in the development of drug delivery systems. They have made a significant impact 
on medical technology by minimizing the size of drug delivery devices from the macro 
to the nano scale and significantly enhancing the performance of existing lifesaving 
drugs.1,2 Mesoporous silica nanoparticles have attracted considerable attention due 
to their ability to enhance solubility of poorly water-soluble drugs, as well as to 
achieve sustained drug release, leading to improved bioavailability.3,4 Advantages 
of mesoporous silica nanoparticles, such as large surface area, high pore volume, 
tunable pore size, and well defined pore structure, as well as mechanical and chemical 
stability and protection of the integrity of the molecular structure of the drug,5–7 make 
them ideal for controlled drug delivery systems. Most recently, mesoporous silica 
nanoparticles were developed for intracellular controlled drug/gene delivery8,9 and 
targeted drug delivery to cancer cells.10,11 Furthermore, the safety of silica materials 
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used as drug delivery systems has been well defined in 
several reports,12,13 which makes them desirable as perfect 
delivery systems. Chervenkov et al12 found that oral (2 g/kg 
bodyweight) administration of silica dioxide xerogels did not 
result in significant changes in the biochemical parameters 
characterizing liver function and gastric mucosal damage.
So far, many attempts have been made to develop sus-
tained-release preparations to improve the release behavior 
of orally delivered water-soluble drugs, such as sustained-
release matrix tablets,14,15 nanostructured liquid crystalline 
matrix,16 surfactant-polymer nanoparticles,17 double-walled 
microspheres,18 and mesoporous silica nanoparticles.3,5 
However, the in vitro sustained-release duration of these 
formulations lasted no longer than 24 hours. Therefore, it is 
desirable to develop a drug-release model that can achieve in 
vitro sustained release for a long period of time. In the present 
study, hollow-type mesoporous silica nanoparticles (HMSNs) 
were prepared and used as an in vitro sustained drug-release 
model for water-soluble drugs. Due to the highly porous 
structure of HMSNs, drugs can be loaded within the pores 
or canals, achieving in vitro sustained release for 72 hours. 
HMSNs have most of the advantages of mesoporous silica 
nanoparticles, but unlike mesoporous silica nanoparticles 
published earlier on, HMSNs possess a spherical shape with 
inner pores and channels and longer-lasting drug release in 
vitro. The possible reason is that, unlike the regularly and 
orderly distributed canals in mesoporous silica nanoparticles, 
the HMSNs prepared in this study possessed irregular and 
disordered canals which may result in prolonged drug release 
because it is harder for the drug to escape from disordered 
canals than from ordered ones.
Silybin meglumine, a commercially used compound of 
silybin and meglumine, was used as the model drug in this 
work. It has been widely used for the treatment of acute 
hepatitis, chronic hepatitis, initial-stage hepatocirrhosis, and 
liver damage due to intoxication because of the   excellent 
  hepatoprotective effect of silybin. Silybin is a naturally occur-
ring polyphenolic flavonoid extracted from the seed of the milk 
thistle (Silybum marianum),19,20 and has been widely used to 
treat certain liver disorders, such as chronic active hepatitis, 
hepatic cirrhosis, as well as alcohol-induced and various types 
of drug-induced and toxin-induced liver damage.21,22 It is 
known that silybin is a poorly water-soluble drug; however, 
once silybin is combined with meglumine, its ionization ability 
increases and silybin meglumine is endowed with high water 
solubility. The present commercial formulation of silybin 
meglumine is in the form of a tablet and patients have to take 
the medicine three times a day in order to maintain an effective 
plasma concentration.   Obviously, it is inconvenient for most 
patients to take medicine so frequently. Therefore, it is impor-
tant to develop a universally applicable technology for pro-
cessing silybin meglumine in order to achieve high-efficacy, 
a long-term drug-release pattern, and reduce the frequency of 
drug administration. Furthermore, such a delivery system must 
be safe after oral or intravenous administration.
Until now, most investigations of silica nanoparticles have 
focused on porous silica nanoparticles and mesoporous silica 
nanoparticles, including preparation methods, drug-loading 
capacity, and in vitro release performance.23–25 Few attempts have 
been made to evaluate their in vivo absorption characteristics, and 
no research has been carried out to study in vitro–in vivo correla-
tions (IVIVCs). Further, the present scientific literature shows that 
no report has been published about HMSNs for sustained drug 
delivery. In a report by Li et al,26 the in vitro controlled release of 
loaded drugs from porous hollow silica nanoparticles could last 
for up to 30 days, but no in vivo investigation was carried out. 
Based on common knowledge, loaded drugs cannot survive up to 
30 days after release in vivo. Previous studies have confirmed that 
the in vitro accumulated release of drug-loaded HMSNs in tradi-
tional dissolution media was less than 20%, but the drug could be 
eliminated within 72 hours following single-dose administration 
in Beagle dogs (data not shown). This inconsistency between in 
vitro dissolution and in vivo absorption has prompted researchers 
to seek out improved dissolution methods or better dissolution 
media in order to obtain better IVIVCs.
The in vitro dissolution medium is an important factor 
in constructing a good in vitro drug-release model. So far, 
many media, such as phosphate buffer solution,27 HCl solu-
tion (pH 1–2),4 and water/ethanol mixture (70:30, v/v),26 have 
been used to dissolve formulations prepared on the basis of 
porous silica nanoparticles, but none of these studies has 
evaluated IVIVCs. A possible reason is that there still remain 
many difficulties in developing appropriate dissolution test 
methods due to fast dissolution of submicron drug substances 
and in separating undissolved particles from dissolution 
medium.28 What is more important is to find a proper dis-
solution medium that can achieve a good IVIVC.
In an effort to address the problems mentioned above, our 
research group attempted to develop a high-efficacy, long-acting 
in vitro drug-release model based on HMSNs for the delivery 
of water-soluble drugs. Water-soluble silybin meglumine was 
directly loaded into HMSNs in this study. The in vitro release 
profiles of silybin meglumine-loaded HMSNs were studied for 
the first time using Na2CO3   solutions with different concentra-
tions (0.01 M, 0.06 M, 0.08 M, and 0.1 M). The treatment 
was repeated for other dissolution media such as   traditional 
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artificial gastric juice (pH 1.2) and artificial intestinal juice 
(pH 6.8). Beagle dogs were used as an in vivo model to study 
pharmacokinetic characteristics after oral administration, and 
the IVIVC was then established. The use of HMSNs together 
with a Na2CO3 solution at a certain concentration is expected 
to be developed into an effective approach to obtain an in vitro 
drug-release model with a sustained-release pattern lasting for 
72 hours, as well as a good IVIVC.
Methods and materials
Materials
Tetraethyl orthosilicate, absolute ethyl alcohol, ammonia 
water, cyclohexane, n-hexanol, and Na2CO3 were purchased 
from Chemical Reagent Co, Ltd, of the China National Phar-
maceutical Group (Shanghai, China). NP-10 was obtained 
from Shanghai Jiafang Trade Co, Ltd (Shanghai, China). The 
animal experiments were performed strictly according to the 
experimental protocols approved by the university ethics com-
mittee for the use of experimental animals, and also conformed 
to the Guide for Care and Use of   Laboratory Animals.
Preparation of empty hMSNs
A 6 mL quantity of nonylphenol 10 (NP-10) was added to 
50 mL of cyclohexane, and shaken together. After adding 
2.2 mL of n-hexanol and 1.8 mL of 25.6% ammonia water, 
the resulting mixture was again agitated for one hour at room 
temperature. Tetraethyl orthosilicate 4.2 mL was slowly 
added to the mixture and agitation was conducted for another 
24 hours at room temperature. A 60 mL quantity of absolute 
ethyl alcohol was then added prior to ultrasound treatment 
for one hour (Wuxi Ultrasonic Devices Factory, Jiangsu, 
China). Centrifugal separation was performed at 15,000 per 
second for 15 minutes and the precipitate was washed three 
times with double-distilled water. After addition of water, 
freezing, and drying of the substance in succession, a powder 
of solid silica nanoparticles was obtained.
After addition of 1 g of the silica nanoparticles to 1000 mL 
of 0.6 mol/L Na2CO3 solution, ultrasound was administered 
for 5 minutes at 65°C and 200 W. The mixture was then cen-
trifugally separated at 15,000 per second for 15 minutes and 
the precipitate was washed three times with double-distilled 
water. The resulting precipitate was then added to 10 mL 
of double-distilled water, followed by freezing and drying 
the substance in succession, and empty HMSNs were thus 
obtained. Fourier transform infrared analysis was carried out 
to examine the residual surfactant (NP-10). No absorption 
band characterizing NP-10 was observed, indicating that the 
surfactant had been completely washed away.
Preparation of silybin meglumine-loaded  
hMSNs
In this study, silybin meglumine was directly loaded into the 
HMSNs. Two grams of silybin meglumine was dissolved in 
20 mL of double-distilled water, in which 1 g of empty HMSNs 
were soaked for 24 hours and then centrifugally separated at 
15,000 per second for 15 minutes. The precipitate was washed 
three times with double-distilled water. It was then added to 
10 mL of double-distilled water, then frozen and dried in 
  succession. Drug-loaded nanoparticles were obtained.
Physicochemical characterization  
of hMSNs
The physicochemical features of HMSNs were characterized 
using transmission electron microscopy and the nitrogen 
adsorption method. The morphology and internal porous 
structure of the samples were observed using a transmission 
electron microscope (JEM-2100, JEOL, Tokyo, Japan). The 
specific surface area, pore volume, and pore diameter of the 
samples were measured by the nitrogen adsorption method 
using a high-speed automated surface area and pore size 
analyzer (Nova 2000, Quantachrome Instruments, Boynton 
Beach, FL) according to the Brunauer-Emmett-Teller and 
Barrett-Joyner-Halenda procedures.
The drug-loading rates of both silybin meglumine-loaded 
HMSNs and silybin meglumine-loaded solid silica nano-
particles were also determined. A 10 mg quantity of silybin 
meglumine-loaded HMSNs and the same amount of silybin 
meglumine-loaded solid silica nanoparticles were added to 
a certain amount of Na2CO3 solution and then water-bathed 
at a certain temperature for 30 minutes. The treatment was 
repeated for the same amount of HMSNs without a loading 
drug which resulted in a blank control solution.
The drug-loading rate was determined via ultraviolet 
spectroscopy (UV-2401PC, Shimadzu, Tokyo, Japan) at a 
wavelength of 288 nm. The blank control solution was used 
as reference. The drug-loading rate was calculated according 
to the following formula:
 
  (1)
In vitro sustained-release studies
The in vitro release profiles of silybin meglumine from the 
sample were determined by a dialysis tubing method using 
dissolution testing apparatus (Tianjin University Radio 
  Factory, Tianjin, China) according to the paddle method 
recorded by the Chinese Pharmacopoeia (2005). Artificial 
Drugloadingrate
Weight of druginHSNsorSSNS
Weight of drugloaded
=
H HSNsorSSNs
× 100%
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gastric juice (pH 1.2), artificial intestinal juice (pH 6.8), 
Na2CO3 solutions with different concentrations (0.01 M 
pH 11.1, 0.06 M pH 11.5, 0.08 M pH 11.6, 0.1 M pH 11.7), 
and 0.01 M NaOH (pH 12) were used as dissolution media in 
this study. The paddles were rotated at 100 rpm for 72 hours. 
The samples were accurately weighed and added to the dialy-
sis bags, which were then fixed on the paddles. The samples 
were then put into 900 mL of artificial gastric juice (pH 1.2) 
or intestinal juice (pH 6.8) as the dissolution medium with 
the temperature adjusted to 37°C ± 0.1°C.
Test fluids were withdrawn at predetermined time inter-
vals from each vessel and then filtered through a 0.45 µm 
membrane filter. The same volume of test fluid removed was 
then replaced by fresh medium. The quantity of silybin in the 
filtrate (20 µL) was analyzed using a high-pressure liquid 
chromatography (HPLC) system (model 510; Waters Cor-
poration, Milford, MA) equipped with an ultraviolet detector 
(model 486; Waters Corporation). The HPLC conditions were 
as follows: reverse-phase column, Nova-pack C18 column 
(3.9 × 150 mm, 5 µm) at 37°C; mobile phase, dipotassium 
hydrogen phosphate (0.05 M): methanol 9.9:11 (v/v) mixture; 
flow rate, 1.0 mL/minute; and detection wavelength, 288 nm. 
All analyses were performed at 37°C and experiments were 
performed at least three times. The standard curve range was 
1.68–31.8 µg/mL.
In vivo absorption study
Animal experiment
Healthy male Beagle dogs weighing 10 ± 2 kg were sub-
jected to fasting overnight before the experiments, but 
allowed free access to water throughout the study. Silybin 
meglumine-loaded HMSNs were administered as an oral 
dose (21.2 mg/kg) to the test group of six dogs.
Serial blood samples of approximately 3 mL were col-
lected at 0.25, 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, 24, 36, 48, 60, 
and 72 hours after oral administration. Plasma obtained after 
centrifugation (10 minutes, 4000 per second) was immediately 
added to 20 µL of internal standard solution (α-naphthol, 
10 µg/mL in methanol) followed by gentle vortex agitation 
for 5 minutes. The mixture was centrifuged for 10 minutes at 
3000 per second, and the organic layer was then transferred to 
a clean vial and evaporated under nitrogen at 30°C. Finally, 
the residue was dissolved in 100 µL of the mobile phase and 
transferred to the HPLC system for analysis.
hPLC analysis
Plasma silybin was determined by HPLC. A Nova-pack 
C18 column (150 mm × 3.9 mm, 5 µm) with a column 
  temperature of 37.5°C and a mobile phase consisting of 
methanol and KH2PO4 (0.05 mol/L) with the ratio of 9.9:11 
at pH 3.8 were used. The eluent was monitored at 288 nm 
with a flow rate of 1 mL/minute. α-Naphthol was used as 
an internal standard.
Calculation of in vivo absorption 
percentage
There are various methods that can be used to calculate the 
in vivo absorption percentage, including Wagner–Nelson 
and Loo–Riegelman methods. The former is applicable 
to a one-compartment model, the later is suitable for a 
two-compartment model, whereas according to the result 
determined by Akaike’s information criterion method, 
which was conducted by using software BAPP2.3 (supplied 
by the Center of Drug Metabolism of China Pharmaceutical 
University, China) in our previous studies, the plasma 
concentration-time data for free silybin released from 
HMSNs were fit to a one-compartment model (data not 
shown). Therefore, the Wagner–Nelson method was used 
in the present work to calculate the in vivo absorption 
fraction:
  f
Ct kC tdt
kC tdt
T
=
+
× ∫
∫
∞
0
0
100%   (2)
In the above formula, f represents the in vivo absorption 
fraction, Ct is the plasma concentration at time point t, and 
k is the elimination rate constant.
Statistical analysis
All values are represented as the mean ± standard deviation. 
Statistical differences between the different groups were 
determined using the Student’s t-test and one-way analysis 
of variance, with a least significant difference post-hoc test 
by SPSS statistical software (SPSS version 15.0, SPSS Inc, 
Chicago, IL). Differences between the two groups were 
considered to be statistically significant at P , 0.01.
Results and discussion
Preparation and physicochemical 
characteristics of hMSNs
So far, a number of studies have been conducted on the 
preparation of porous silica spheres by the modified 
  Stober   methods, in which cationic surfactants were used as 
porogens.29–31 In the present study, a Na2CO3 solution and 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
756
Cao et alInternational Journal of Nanomedicine 2012:7
ultrasound were used to make pores and canals within the 
silica spheres. After lyophilization, the hollow-type mesopo-
rous silica nanoparticles were then obtained. In this work, 
Na2CO3 solution was used innovatively to dissolve the silica 
partially under certain conditions. The resulting HMSNs were 
highly porous with a uniform small size, and had disordered 
holes, as well as a large surface area.
Transmission electron microscopy was used to charac-
terize the morphology and porous structure of the HMSNs. 
It was observed that the empty/drug-loaded HMSNs with/
without phosphotungstic acid staining, showed images of 
empty/drug-loaded HMSNs (with phosphotungstic acid 
staining) being less desirable as compared with the other 
component without phosphotungstic acid staining (data not 
shown). Thus, the transmission electron microscopy without 
phosphotungstic acid staining was used in the present study. 
Figure 1 shows transmission electron microscopic images 
of solid silica nanoparticles and HMSNs before and after 
drug-loading, in which a spherical appearance and uniformly 
distributed particle size within the range of 50–100 nm were 
observed. In addition, the highly porous inner structure 
of the empty HMSNs (Figure 1B) was clearly visible in 
comparison with the solid silica nanoparticles (Figure 1A). 
When loaded with drugs, the holes and canals on the surface 
of the particles disappeared, as shown in Figure 1C (silybin 
meglumine-loaded HMSNs). The most probable reason to 
explain this observation is that most of the canals and holes 
within the empty HMSNs were filled with drug.
In this study, to identify the specific surface area, pore 
volume, and pore diameter of the samples, the nitrogen 
adsorption method was employed. The results are shown 
in Figure 2, in which the nitrogen adsorption–desorption 
isotherms of both solid silica nanoparticles and HMSNs 
before and after drug-loading are demonstrated. The nitrogen 
adsorption–desorption isotherms for solid silica nanoparticles 
completely overlapped, indicating no presence of pores, while 
an adsorption isotherm of empty HMSNs similar to Type II 
Langmuir adsorption isotherms and a hysteresis loop in the 
range of relative pressure from 0.696 to 0.989 indicated 
the presence of pores or canals in HMSNs.32 The average 
pore diameter of the empty HMSNs was 2.74 nm and the 
pore size was uniformly distributed within a relatively narrow 
range, between 1 nm and 6 nm. The empty HMSNs with an 
ultranarrow pore size (2.74 nm on average) prepared in this 
work were obviously smaller than that of the porous silica 
nanoparticles reported by Zhang et al.3 When loaded with 
drug, HMSNs showed no hysteresis loop, suggesting that 
most pores within the HMSNs were completely filled with 
drug. These results are in agreement with the transmission 
electron microscopic image in Figure 1. Additionally,   nitrogen 
adsorption results demonstrated that the HMSNs had a much 
larger specific surface area (385.89 ± 1.12 m2/g) than the 
solid silica nanoparticles (5.84 ± 0.26 m2/g), indicating the 
highly porous structure of HMSNs. After adsorption of silybin 
meglumine, a significant decrease was observed in the surface 
area of HMSNs (6.42 m2/g) and the pore diameter (1.68 nm), 
indicating successful loading of silybin meglumine.
The drug-loading rate of the silybin meglumine-loaded 
HMSNs was 58.91% ± 0.39%, while the drug-loading rate 
of silybin meglumine-loaded solid silica nanoparticles was 
only 5.78% ± 0.12%. The results fully demonstrate the 
advantages of empty HMSNs over solid silica nanoparticles 
in drug delivery.
In vitro release studies
The in vitro release profiles of silybin meglumine from 
HMSNs are illustrated in Figure 3, in which silybin 
meglumine-loaded solid silica nanoparticles were used as a 
comparison. In order to select a suitable dissolution medium, 
several kinds of solutions were tested, including artificial 
Figure 1 Images of (A) TEM image for solid silica nanoparticles, (B) TEM image of empty hMSNs, and (C) TEM image of silybin meglumine-loaded hMSNs.
Abbreviations: hMSNs, hollow-type mesoporous silica nanoparticles; TEM, transmission electron microscopy.
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gastric juice (pH 1.2) and artificial intestinal juice (pH 6.8), 
0.01 M NaOH solution (pH 12), as well as Na2CO3 solutions 
with different concentrations (0.01 M pH 11.1, 0.06 M pH 
11.5, 0.08 M pH 11.6, and 0.1 M pH 11.7). For the preliminary 
research, artificial gastric and intestinal juices were used to 
dissolve samples according to the paddle method recorded by 
the Chinese Pharmacopoeia (2005). As shown in Figure 3A, 
the accumulated release percentages of silybin meglumin 
from silybin meglumine-loaded HMSNs in artificial gastric 
and intestinal juices were less than 20% within 72 hours. It 
is obvious that artificial gastric and intestinal juices were not 
suitable for in vitro dissolution of silybin meglumine-loaded 
HMSNs, and more investigations were needed in order to 
find a more appropriate dissolution media. Therefore, NaOH 
and Na2CO3 solutions were introduced and the in vitro 
release profiles of silybin meglumine-loaded HMSNs are 
presented in Figure 3B, which show the slowest release rate 
in a 0.01 M Na2CO3 solution and the fastest release rate in a 
0.1 M Na2CO3 solution. It is known that silybin meglumine 
is an ammonium salt which is chemically stable in basic 
media. An accelerating dissolution rate was observed with 
increasing Na2CO3 concentration. Significant enhancement 
of dissolution was observed in 0.06 M, 0.08 M, and 0.1 M 
Na2CO3 solutions as compared with that in artificial gastric 
or intestinal juices. A similarly rapid release was also 
observed in 0.06 M and 0.08 M Na2CO3 solutions, with an 
accumulative release rate of approximately 59% and 63% 
at 12 hours, respectively, but a significantly faster release 
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from 0.1 M Na2CO3 solution with an accumulative release 
rate of approximately 94% at 12 hours. After that silybin 
meglumine-loaded HMSNs in a 0.08 M Na2CO3 solution 
was faster than that of a 0.06 M Na2CO3 solution. For 
0.08 M Na2CO3 solution, the accumulative release rate 
was 80.0% at 24 hours, followed by a slow increase up to 
92.3% at 72 hours, while the accumulative release rate was 
only 62.8% at 24 hours and 77.4% at 72 hours for 0.06 M 
Na2CO3 solution. One of the possible mechanisms for this 
phenomenon is that silica exhibited weak acidity33,34 and 
Na2CO3 solution exhibited weak alkalinity, so that an acid-
base chemical reaction took place between silica and Na2CO3, 
resulting in the water-soluble salt Na2SiO3 that existed in 
ion form in water. It could be speculated that the HMSN 
matrix disintegrated into many microparticles in Na2CO3 
solution, similar to the disintegration of common tablets 
but at a much slower rate. Furthermore, in Na2CO3 solutions 
with different concentrations, there were different degrees 
of silica dissolution, resulting in different drug-release 
rates. Therefore, the in vitro release rate of loaded drugs 
can be controlled by using Na2CO3 solutions with different 
concentrations as the dissolution media. In other words, drug 
release from HMSNs could be affected by the pH value of 
the media. It is well known that silica is an acidic oxide 
that usually reacts with a basic oxide. As a result, silica can 
dissolve in alkaline media (pH . 7) with stronger alkalinity 
(a higher pH value), resulting in a faster reaction. Thus, 
with the increase in Na2CO3 concentration, the pH value of 
the media increased as well, leading to faster dissolution 
of HMSNs and quicker release of loaded drugs. However, 
according to the results (Figure 3B), a slower release profile 
was seen from 0.01 M NaOH solution with a pH value 
of 12 than from 0.06 M Na2CO3 solution. Therefore, pH 
value was not the only factor that in vitro degradation of 
HMSNs but also the concentration. The exact reason for the 
observation is still unknown and further investigation of the 
dissolution mechanism will be carried out in future works.
Figure 3C shows the in vitro release profiles for silybin 
meglumine from silybin meglumine-loaded solid silica 
nanoparticles in artificial gastric and intestinal juices. The 
accumulated release achieved a constant level at 0.5 hours for 
solid silica nanoparticles in artificial intestinal juice (with an 
accumulated release rate of 100%) and at one hour for artifi-
cial gastric juice (with an accumulated release rate of 70%). 
These results confirm the advantages of HMSNs over solid 
silica nanoparticles in drug storage and sustained release.
In this study, Na2CO3 solutions were used as dissolution 
media for the first time by our research group. It is of great 
significance for discovering a desirable in vitro dissolution 
model for drug-loaded HMSNs with long-term release for 
72 hours.
In vivo absorption study
The oral absorption of silybin meglumine from HMSNs was 
studied in fasting Beagle dogs. The fasting state was selected 
to exclude the effect of food lipids, which can be confused 
with the effect of internal lipids. Because silybin meglumine 
is a compound of silybin and meglumine, it was speculated 
that the compound could be easily degraded into silybin and 
meglumine in the in vivo environment. Thus, silybin blood 
concentration was used as an indicator of silybin meglumine 
absorption in vivo.
Table  1  Mean  plasma  concentration-time  data  for  silybin 
meglumine-loaded  incorporated  into  hollow-type  silica 
nanoparticles following a single dose
Time points  
(hours)
Mean plasma concentration  
of silybin (ng/mL)
Standard  
deviationa
0.25 104.03 8.28
0.5 129.31 8.15
1 147.31 7.11
2 180.97 4.50
4 203.38 4.90
6 254.55 19.47
8 283.00 12.47
10 312.10 14.15
12 323.90 7.03
16 321.79 11.37
24 324.76 14.36
36 271.03 14.93
48 253.09 7.66
60 209.13 18.45
72 110.17 8.29
Note: aBoth positive and negative standard deviations were included.
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Figure  4  In  vivo  absorption  fraction  of  silybin  meglumine-loaded  hollow-type 
mesoporous silica nanoparticles generated from the Wagner–Nelson method.
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Figure 5 Correlations between in vitro dissolution fractions and in vivo absorption fractions. (A) IVIVC of silybin meglumine-loaded HMSNs in artificial gastric juice; 
(B) IVIVC of silybin meglumine-loaded HMSNs in artificial intestinal juice; (C) IVIVC of silybin meglumine-loaded hMSNs in 0.06 M Na2CO3 solution; (D) IVIVC of silybin 
meglumine-loaded hMSNs in 0.08 M Na2CO3 solution; and (E) IVIVC of silybin meglumine-loaded hMSNs in 0.1 M Na2CO3 solution.
Abbreviations: hMSNs, hollow-type mesoporous silica nanoparticles; IVIVC, in vitro–in vivo correlations.
The mean plasma concentration-time data for silybin 
meglumine-loaded HMSNs following a single dose are pre-
sented in Table 1. Based on these data, the percentages of 
silybin absorbed at specific time points were calculated from 
the plasma concentration data by using the Wagner–Nelson 
method,35 as shown in Figure 4.
In vitro-in vivo correlation
The correlations between in vitro and in vivo data for silybin 
meglumine-loaded HMSNs and silybin meglumine tablets 
were investigated. Three levels of IVIVC are classified 
according to the US Food and Drug Administration.36 A level 
A correlation, ie, a point-to-point relationship between in 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
760
Cao et alInternational Journal of Nanomedicine 2012:7
vitro dissolution and in vivo absorption, was used in this 
present work.
Figure 5 showed the correlations between the in vitro 
dissolved fractions and in vivo absorbed fractions for silybin 
meglumine-loaded HMSNs and silybin meglumine tablets 
in the individual beagle dogs. The fractions dissolved in 
artificial gastric juice (pH 1.2), artificial intestinal juice 
(pH 6.8), and 0.06 M, 0.08 M, and 0.1 M Na2CO3 solutions 
were plotted against the fractions absorbed in 72 hours in the 
fasting condition, in order to find out the appropriate in vitro 
dissolution medium leading to better IVIVC. According to 
the statistics, the linear relationships between the in vitro 
dissolved fractions and the in vivo absorbed fractions for the 
silybin meglumine-loaded HMSNs in artificial gastric juice 
(R2 = 0.9287, as shown in Figure 5A) and artificial intestinal 
juice (R2 = 0.7689, as shown in Figure 5B) were not significantly 
correlated. In the case of the 0.06 M Na2CO3 solution as the 
in vitro dissolution medium, the value of the correlation 
coefficient R2 was 0.9741 (Figure 5C). This value was lower 
than that for the 0.08 M Na2CO3 solution, which exhibited 
a correlation coefficient R2 value of 0.9931 (Figure 5D). 
Interestingly, when the concentration of Na2CO3 solution 
increased to 0.1 M, the correlation coefficient R2 decreased 
dramatically (R2 = 0.5600). This phenomenon indicated that 
the use of Na2CO3 solution with concentration lower than 0.08 
M gave a better IVIVC with increasing Na2CO3 concentration, 
but when the concentration of Na2CO3 solution was beyond 
0.08 M, the correlation coefficient reduced with increasing 
Na2CO3 concentration. The exact reasons for this will be 
addressed in future work. According to the results of IVIVC, 
the 0.08 M Na2CO3 solution was the most effective dissolution 
medium for silybin meglumine-loaded HMSNs. In the case 
of the 0.08 M Na2CO3 solution, the in vitro dissolution rate 
was not the same as the in vivo absorption rate in each subject 
(Figure 5D). This difference could be due to the differences 
between the simple in vitro environment and the complex in 
vivo environment for dissolution. In addition, gastric emptying 
and intestinal transit would regulate the absorption process,24 
and therefore result in the differences observed between in 
vitro dissolution rates and in vivo absorption rates.
In summary, Na2CO3 solutions had been reported in this 
study for the first time as an in vitro dissolution medium for 
drug-loaded HMSNs, which exhibited excellent level A IVIVC. 
The drug-release model developed in this study achieved in 
vivo sustained release lasting for 72 hours, with advantages 
such as fast action, high efficacy, and long-lasting action. The 
results of this work have therefore had a considerable impact 
on the construction of sustained-release systems.
Conclusion
In this study, silybin meglumine was used as the model drug, 
and was loaded into HMSNs. The silybin meglumine-loaded 
HMSNs were successfully developed to enhance in vitro dis-
solution and in vivo absorption, and demonstrated an excel-
lent IVIVC. The results of transmission electron microscopy 
and nitrogen adsorption showed that the empty HMSNs 
had a large specific surface area (385.89 m2/g) and a small 
pore size (average pore diameter of 2.74 nm), which led to 
a relatively large drug-loading capacity (58.91% ± 0.39%). 
The in vitro dissolution studies conducted in different media 
revealed that Na2CO3 solutions of particular concentra-
tions could achieve highly effective, long-acting, sustained 
release lasting for 72 hours. The results of IVIVC showed 
that HMSNs in 0.08 M Na2CO3 solution had a correlation 
coefficient R2 value of 0.9931, while the correlation coef-
ficient R2 values for the artificial gastric and intestinal juices 
were only 0.9287 and 0.7689, respectively. The IVIVC 
investigated in this work indicated that HMSNs, together 
with a Na2CO3 solution, could achieve an excellent linear 
relationship between the in vitro dissolution and in vivo 
absorption for up to 72 hours.
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